Renal cell carcinoma: Evolving approaches to advanced non-clear cell carcinoma

Oncology Reviews

Volumn 1, Issue 3, 2007, Pages 170-176

  Heng, Daniel Y C ^b   Bukowski, Ronald M ^a,b  

^a Cleveland Clinic Taussig Cancer Center ^*  (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chromophobe; Collecting duct; Non clear cell; Papillary; Renal cell cancer; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

EID: 57449092066     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-007-0020-6     Document Type: Review

References (26)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
2. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477-2490 (Pubitemid 41770167)
3. Kovacs G, Akhtar M, Beckwith BJ et al (1997) The heidelberg classification of renal cell tumours. J Pathol 183:131-133
4. Kwak C, Park YH, Jeong CW et al (2007) Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317-323 (Pubitemid 46355508)
5. Cheville JC, Lohse CM, Zincke H et al (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-624 (Pubitemid 36514472)
6. Beck SD, Patel MI, Snyder ME et al (2004) Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71-77
7. Patard JJ, Leray E, Rioux-Leclercq N et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 23:2763-2771 (Pubitemid 46179466)
8. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537-544 (Pubitemid 27293491)
9. Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the birthogg-dube syndrome. Am J Surg Pathol 26:1542-1552
10. Fleming S, Lewi HJ (1986) Collecting duct carcinoma of the kidney. Histopathology 10:1131-1141 (Pubitemid 17205211)
11. Moch H, Gasser T, Amin MB et al (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A swiss experience with 588 tumors. Cancer 89:604-614 (Pubitemid 30640107)
12. Pignot G, Elie C, Conquy S et al (2007) Survival analysis of 130 patients with papillary renal cell carcinoma: Prognostic utility of type 1 and type 2 subclassification. Urology 69:230-235 (Pubitemid 46274917)
13. Ronnen EA, Kondagunta GV, Ishill N, et al (2006) Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107:2617-2621 (Pubitemid 44845616)
14. Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381 (Pubitemid 34441667)
15. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
16. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
17. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
18. Escudier B, Koralewski P, Pluzanska A et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon- a2a as firstline therapy in metastatic renal cell carcinoma. J Clin Oncol 25:3
19. Plantade A, Choueiri T, Escudier B et al (2007) Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 25:5037
20. Gore ME, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:5010
21. Stadler WM, Figlin RA, Ernstoff MS et al (2007) The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 25:5036
22. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
23. Dutcher JP, Szczylik C, Tannir N et al (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25:5033
24. Eder JP, Heath E, Appleman L et al (2007) Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 25:3526
25. Garcia A, Rosen L, Cunningham CC et al (2007) Phase 1 study of ARQ 197, a selective inhibitor of the c-met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J Clin Oncol 25:3525
26. Ross RW, Stein M, Sarantopoulos J et al (2007) A phase II study of the c-met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 25:15601